Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: Results of a national survey

European Respiratory Journal

Volumn 51, Issue 3, 2018, Pages

  Lim, Dodge R ^a   Dean, Anna S ^b   Taguinod Santiago, Mary Rosary ^c   Borbe Reyes, Angeli ^a   Cabibbe, Andrea Maurizio ^d   Zignol, Matteo ^b   Basilio, Ramon P ^a   Garfin, Anna Marie Celina ^c   Ama, Maria Cecilia G ^a  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c DEPARTMENT OF HEALTH   (Philippines)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; GENE SEQUENCE; GYRA GENE; GYRB GENE; HUMAN; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHILIPPINES; PREVALENCE; PRIORITY JOURNAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MUTATION; PROGNOSIS; QUESTIONNAIRE;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHILIPPINES; PREVALENCE; PROGNOSIS; SURVEYS AND QUESTIONNAIRES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85056587525     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02571-2017     Document Type: Letter

References (15)

1. Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
2. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015; 45: 150-160.
3. Ahmad Khan F, Salim MAH, du Cros P, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: Individual patient data and aggregate data meta-analyses. Eur Respir J 2017; 50: 1700061.
4. Uplekar M, Weil D, Lonnroth K, et al. WHO's new End TB strategy. Lancet 2015; 385: 1799-1801.
5. Zignol M, Dean AS, Falzon D, et al. Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. N Engl J Med 2016; 375: 1081-1089.
6. World Health Organization. Global tuberculosis report 2017 (WHO/HTM/TB/2017.23). Geneva, World Health Organization, 2017.
7. Philippine Nationwide Tuberculosis Drug Resistance Survey Team. Nationwide drug resistance survey of tuberculosis in the Philippines. Int J Tuberc Lung Dis 2009; 13: 500-507.
8. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. www.who.int/tb/ publications/2015/drs_guidelines/en/ Date last updated: June, 2015. Date last accessed: October 5, 2017.
9. Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 49: 1701354.
10. Department of Health. National Tuberculosis Control Programme: Manual of Procedures. 5th Edn. www.doh.gov. ph/sites/default/files/publications/MOP_Final_a.pdf Date last updated: 2014. Date last accessed: June 18, 2017.
11. Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: Results from a multicountry surveillance project. Lancet Infect Dis 2016; 16: 1185-1192.
12. Food and Drug Administration. Antimicrobial Resistance. DOH-FDA Advisory No. 2012-017. www.fda.gov.ph/ attachments/article/38/DOH-FDA_Advisory_No_2012-017.pdf Date last updated: November 29, 2012. Date last accessed: October 20, 2017.
13. Whitfield MG, Warren RM, Streicher EM, et al. Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 micrograms per milliliter in MGIT. J Clin Microbiol 2015; 53: 3633-3635.
14. Willby M, Sikes RD, Malik S, et al. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 5427-5434.
15. Zignol M, Cabibbe AM, Dean AS, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: A multi-country population-based study. Lancet Infect Dis; In press.